SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2024-05-10** | Period of Report: **2024-05-10**
SEC Accession No. 0001193125-24-136088

([HTML Version](#) on secdatabase.com)

FILER

Bellevue Life Sciences Acquisition Corp.
CIK:**1840425**| IRS No.: **845052822** | State of Incorp.:**DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **001-41390** | Film No.: **24934397**
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address
10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004

Business Address
10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004
425-635-7700

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2024

BELLEVUE LIFE SCIENCES ACQUISITION CORP.
(Exact Name of Registrant as Specified in Charter)

Delaware	**001-41390**	**84-5052822**
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

10900 NE 4th Street, Suite 2300, Bellevue, WA	**98004**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code (425) 635-7700

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of common stock, one redeemable warrant and one right	BLACU	The Nasdaq Stock Market LLC
Common stock, par value $0.0001 per share	BLAC	The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share	BLACW	The Nasdaq Stock Market LLC
Right to receive one-tenth (1/10) of one share of common stock	BLACR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

<div align="right">Emerging growth company ☒</div>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.   Other Events.

Adjournment of Special Meeting of Stockholders

As previously announced, Bellevue Life Sciences Acquisition Corp. (the "***Company***") has called and provided a notice of a special meeting of stockholders (the "***Special Meeting***") to be held on May 10, 2024, at 10:00 a.m. Pacific time, at 925 Fourth Avenue, Suite 2900, Seattle, WA 98104, to consider and vote upon the matters described in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "***SEC***") on April 26, 2024 (the "***Proxy Statement***").

On May 10, 2024, the Company convened the Special Meeting as scheduled and adjourned the Special Meeting without any business being conducted. As announced at the Special Meeting, it will be reconvened at 9:00 a.m. Pacific time on Tuesday, May 14, 2024.

The Company's stockholders will be able to attend the Special Meeting at 925 Fourth Avenue, Suite 2900, Seattle, WA 98104.

The Company plans to continue to solicit proxies from stockholders during the period prior to the Special Meeting. Only the holders of the Company's common stock as of the close of business on April 18, 2024, the record date for the Special Meeting, are entitled to vote at the Special Meeting.

Reversal of Redemption Requests

In light of the adjournment of the Special Meeting, any stockholder who has previously tendered its shares for redemption and now decides that it does not want to redeem its shares, the stockholder may still withdraw the tender. If you delivered your shares for redemption to the transfer agent and decide prior to the vote at the Special Meeting (now scheduled for 9:00 a.m. Pacific time on May 14, 2024) not to redeem your public shares, you may request that the transfer agent return the shares (physically or electronically). You may make such request by contacting the transfer agent at:

<div align="center">

Continental Stock Transfer & Trust Company
1 State Street, 30th Floor,
New York, New York 10004,
Attn: SPAC Redemption Team
E-mail: spacredemptions@continentalstock.com

</div>

Forward-Looking Statements

This Current Report on Form 8-K contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the Company's financial position, business strategy and the plans and objectives of management for future operations, including as they relate to a business combination. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. They involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by these statements. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this Current Report on Form 8-K, words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "strive," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When the Company discusses its strategies or plans, including as they relate to a business combination, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, the Company's management. Actual results and stockholders' value will be affected by a variety of risks and factors, including, without limitation, international, national and local economic conditions, merger, acquisition and business combination risks, financing risks, geo-political risks, acts of terror or war, and those risk factors described under "Item 1A. Risk Factors" of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on April 17, 2024, in the section titled "Risk Factors" contained in our prospectus dated February 9, 2023, and in other reports the Company files with the SEC. Many of the risks and factors that will determine these results and stockholders' value are beyond the Company's ability to control or predict.

All such forward-looking statements speak only as of the date of this Current Report on Form 8-K. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. All subsequent written or oral forward-looking statements attributable to us or persons acting on the Company's behalf are qualified in their entirety by this "Forward-Looking Statements" section.

No Offer or Solicitation

This Current Report on Form 8-K shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This Current Report on Form 8-K shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

The Company and its directors, executive officers, other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies from the securityholders of the Company in favor of the approval of the proposals as described in the Proxy Statement. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of the Company's directors and officers in the Proxy Statement, which may be obtained free of charge from the sources indicated above.

Additional Information and Where to Find It

The Company urges investors, stockholders and other interested persons to read the Proxy Statement as well as other documents filed by the Company with the SEC, because these documents will contain important information about the Company and the Extension. Stockholders may obtain copies of the Proxy Statement, without charge, at the SEC's website at www.sec.gov or by directing a request to: Advantage Proxy, Inc., P.O. Box 10904, Yakima, WA 98909, Attn: Karen Smith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 10, 2024

<div align="right">

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

By: /s/ Kuk Hyoun Hwang

Name: Kuk Hyoun Hwang
Title: Chief Executive Officer

</div>

Document And Entity Information [Line Items]

Amendment Flag	false
Entity Central Index Key	0001840425
Document Type	8-K
Document Period End Date	May 10, 2024
Entity Registrant Name	BELLEVUE LIFE SCIENCES ACQUISITION CORP.
Entity Incorporation State Country Code	DE
Entity File Number	001-41390
Entity Tax Identification Number	84-5052822
Entity Address, Address Line One	10900 NE 4th Street
Entity Address, Address Line Two	Suite 2300
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	(425)
Local Phone Number	635-7700
Written Communications	true
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]

Document And Entity Information [Line Items]

Security 12b Title	Units, each consisting of one share of common stock, one redeemable warrant and one right
Trading Symbol	BLACU
Security Exchange Name	NASDAQ

Common Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title	Common stock, par value $0.0001 per share
Trading Symbol	BLAC
Security Exchange Name	NASDAQ

Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]

Document And Entity Information [Line Items]

Security 12b Title	Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share
Trading Symbol	BLACW

[Security Exchange Name](#)	NASDAQ
[Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]](#)	
[Document And Entity Information [Line Items]](#)	
[Security 12b Title](#)	Right to receive one-tenth (1/10) of one share of common stock
[Trading Symbol](#)	BLACR
[Security Exchange Name](#)	NASDAQ

```
{
"version": "2.2",
"instance": {
"d799992d8k.htm": {
"nsprefix": "blacu",
"nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240510",
"dts": {
"schema": {
"local": [
"blacu-20240510.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
"https://xbrl.sec.gov/country/2023/country-2023.xsd",
"https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
"https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
]
},
"definitionLink": {
"local": [
"blacu-20240510_def.xml"
]
},
"labelLink": {
"local": [
"blacu-20240510_lab.xml"
]
},
"presentationLink": {
"local": [
"blacu-20240510_pre.xml"
]
},
"inline": {
"local": [
"d799992d8k.htm"
]
}
},
"keyStandard": 24,
"keyCustom": 0,
"axisStandard": 1,
"axisCustom": 0,
"memberStandard": 1,
"memberCustom": 3,
"hidden": {
"total": 2,
"http://xbrl.sec.gov/dei/2023": 2
},
"contextCount": 5,
"entityCount": 1,
"segmentCount": 4,
"elementCount": 33,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2023": 33
},
"report": {
"R1": {
"role": "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation",
"longName": "100000 - Document - Document and Entity Information",
"shortName": "Document and Entity Information",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "duration_2024-05-10_to_2024-05-10",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"p",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d799992d8k.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "duration_2024-05-10_to_2024-05-10",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"p",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d799992d8k.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "AmendmentFlag",
"presentation": [
"http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"terseLabel": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "CityAreaCode",
"presentation": [
"http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"terseLabel": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"us-gaap_ClassOfStockDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ClassOfStockDomain",
"presentation": [
"http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Class of Stock [Domain]",
"terseLabel": "Class of Stock [Domain]"
}
}
},
"auth_ref": []
},
"us-gaap_CommonStockMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommonStockMember",
"presentation": [
"http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Common Stock [Member]",
"terseLabel": "Common Stock [Member]"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
```

```
      "label": "Cover [Abstract]",
      "terseLabel": "Cover [Abstract]",
      "documentation": "Cover page."
     }
    }
   },
   "auth_ref": []
  },
  "blacu_DocumentAndEntityInformationLineItems": {
   "xbrltype": "stringItemType",
   "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240510",
   "localname": "DocumentAndEntityInformationLineItems",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Document And Entity Information [Line Items]",
      "terseLabel": "Document And Entity Information [Line Items]"
     }
    }
   },
   "auth_ref": []
  },
  "blacu_DocumentAndEntityInformationTable": {
   "xbrltype": "stringItemType",
   "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240510",
   "localname": "DocumentAndEntityInformationTable",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Document And Entity Information [Table]",
      "terseLabel": "Document And Entity Information [Table]"
     }
    }
   },
   "auth_ref": []
  },
  "dei_DocumentPeriodEndDate": {
   "xbrltype": "dateItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "DocumentPeriodEndDate",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Document Period End Date",
      "terseLabel": "Document Period End Date",
      "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
     }
    }
   },
   "auth_ref": []
  },
  "dei_DocumentType": {
   "xbrltype": "submissionTypeItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "DocumentType",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Document Type",
      "terseLabel": "Document Type",
      "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
     }
    }
   },
   "auth_ref": []
  },
  "dei_EntityAddressAddressLine1": {
   "xbrltype": "normalizedStringItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityAddressAddressLine1",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Address, Address Line One",
      "terseLabel": "Entity Address, Address Line One",
      "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
     }
    }
   },
   "auth_ref": []
  },
  "dei_EntityAddressAddressLine2": {
   "xbrltype": "normalizedStringItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityAddressAddressLine2",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Address, Address Line Two",
      "terseLabel": "Entity Address, Address Line Two",
      "documentation": "Address Line 2 such as Street or Suite number"
     }
    }
   },
   "auth_ref": []
  },
  "dei_EntityAddressCityOrTown": {
   "xbrltype": "normalizedStringItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityAddressCityOrTown",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Address, City or Town",
      "terseLabel": "Entity Address, City or Town",
      "documentation": "Name of the City or Town"
     }
    }
   },
   "auth_ref": []
  },
  "dei_EntityAddressPostalZipCode": {
   "xbrltype": "normalizedStringItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityAddressPostalZipCode",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Address, Postal Zip Code",
      "terseLabel": "Entity Address, Postal Zip Code",
      "documentation": "Code for the postal or zip code"
     }
    }
   },
   "auth_ref": []
  },
  "dei_EntityAddressStateOrProvince": [
   "xbrltype": "stateOrProvinceItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityAddressStateOrProvince",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Address, State or Province",
      "terseLabel": "Entity Address, State or Province",
      "documentation": "Name of the state or province."
     }
    }
   },
   "auth_ref": []
  },
  "dei_EntityCentralIndexKey": {
   "xbrltype": "centralIndexKeyItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityCentralIndexKey",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Central Index Key",
      "terseLabel": "Entity Central Index Key",
      "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
     }
    }
   },
   "auth_ref": [
    "r1"
   ]
  },
  "dei_EntityEmergingGrowthCompany": {
   "xbrltype": "booleanItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityEmergingGrowthCompany",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Emerging Growth Company",
      "terseLabel": "Entity Emerging Growth Company",
      "documentation": "Indicate if registrant meets the emerging growth company criteria."
     }
    }
   },
   "auth_ref": [
```

    "r1"
   ]
  },
  "dei_EntityExTransitionPeriod": {
   "xbrltype": "booleanItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityExTransitionPeriod",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Ex Transition Period",
      "terseLabel": "Entity Ex Transition Period",
      "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
     }
    }
   },
   "auth_ref": [
    "r7"
   ]
  },
  "dei_EntityFileNumber": {
   "xbrltype": "fileNumberItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityFileNumber",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity File Number",
      "terseLabel": "Entity File Number",
      "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
     }
    }
   },
   "auth_ref": []
  },
  "dei_EntityIncorporationStateCountryCode": {
   "xbrltype": "edgarStateCountryItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityIncorporationStateCountryCode",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Incorporation State Country Code",
      "terseLabel": "Entity Incorporation State Country Code",
      "documentation": "Two-character EDGAR code representing the state or country of incorporation."
     }
    }
   },
   "auth_ref": []
  },
  "dei_EntityRegistrantName": {
   "xbrltype": "normalizedStringItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityRegistrantName",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Registrant Name",
      "terseLabel": "Entity Registrant Name",
      "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
     }
    }
   },
   "auth_ref": [
    "r1"
   ]
  },
  "dei_EntityTaxIdentificationNumber": {
   "xbrltype": "employerIdItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "EntityTaxIdentificationNumber",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Entity Tax Identification Number",
      "terseLabel": "Entity Tax Identification Number",
      "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
     }
    }
   },
   "auth_ref": [
    "r1"
   ]
  },
  "dei_LocalPhoneNumber": {
   "xbrltype": "normalizedStringItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "LocalPhoneNumber",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Local Phone Number",
      "terseLabel": "Local Phone Number",
      "documentation": "Local phone number for entity."
     }
    }
   },
   "auth_ref": []
  },
  "dei_PreCommencementIssuerTenderOffer": {
   "xbrltype": "booleanItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "PreCommencementIssuerTenderOffer",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Pre Commencement Issuer Tender Offer",
      "terseLabel": "Pre Commencement Issuer Tender Offer",
      "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
     }
    }
   },
   "auth_ref": [
    "r3"
   ]
  },
  "dei_PreCommencementTenderOffer": {
   "xbrltype": "booleanItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "PreCommencementTenderOffer",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Pre Commencement Tender Offer",
      "terseLabel": "Pre Commencement Tender Offer",
      "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
     }
    }
   },
   "auth_ref": [
    "r4"
   ]
  },
  "blacu_RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member": {
   "xbrltype": "domainItemType",
   "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240510",
   "localname": "RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]",
      "terseLabel": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]"
     }
    }
   },
   "auth_ref": []
  },
  "blacu_RightToReceiveOnetenth110OfOneShareOfCommonStockMember": {
   "xbrltype": "domainItemType",
   "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240510",
   "localname": "RightToReceiveOnetenth110OfOneShareOfCommonStockMember",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]",
      "terseLabel": "Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]"
     }
    }
   },
   "auth_ref": []
  },
  "dei_Security12bTitle": {
   "xbrltype": "securityTitleItemType",
   "nsuri": "http://xbrl.sec.gov/dei/2023",
   "localname": "Security12bTitle",
   "presentation": [
    "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
   ],
   "lang": {
    "en-us": {
     "role": {
      "label": "Security 12b Title",
      "terseLabel": "Security 12b Title",
      "documentation": "Title of a 12(b) registered security."
     }

      }
    },
    "auth_ref": [
     "r0"
    ]
   },
   "dei_SecurityExchangeName": {
    "xbrltype": "edgarExchangeCodeItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "SecurityExchangeName",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Security Exchange Name",
       "terseLabel": "Security Exchange Name",
       "documentation": "Name of the Exchange on which a security is registered."
      }
     }
    },
    "auth_ref": [
     "r2"
    ]
   },
   "dei_SolicitingMaterial": {
    "xbrltype": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "SolicitingMaterial",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Soliciting Material",
       "terseLabel": "Soliciting Material",
       "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
      }
     }
    },
    "auth_ref": [
     "r5"
    ]
   },
   "us-gaap_StatementClassOfStockAxis": {
    "xbrltype": "stringItemType",
    "nsuri": "http://fasb.org/us-gaap/2023",
    "localname": "StatementClassOfStockAxis",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Class of Stock [Axis]",
       "terseLabel": "Class of Stock [Axis]"
      }
     }
    },
    "auth_ref": []
   },
   "dei_TradingSymbol": {
    "xbrltype": "tradingSymbolItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "TradingSymbol",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Trading Symbol",
       "terseLabel": "Trading Symbol",
       "documentation": "Trading symbol of an instrument as listed on an exchange."
      }
     }
    },
    "auth_ref": []
   },
   "blacu_UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member": {
    "xbrltype": "domainItemType",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240510",
    "localname": "UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]",
       "terseLabel": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]"
      }
     }
    },
    "auth_ref": []
   },
   "dei_WrittenCommunications": {
    "xbrltype": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "WrittenCommunications",
    "presentation": [
     "http://BellevueLifeSciencesAcquisitionCorp.com//20240510/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
     "en-us": {
      "role": {
       "label": "Written Communications",
       "terseLabel": "Written Communications",
       "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
      }
     }
    },
    "auth_ref": [
     "r6"
    ]
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}